Cargando…

Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection

Lung transplant recipients (LTRs) have an increased risk of COVID-19–related morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal antibody combination granted Emergency Use Authorization approval by the US Food and Drug Administration for COVID-19 pre-exposure prophy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sindu, Devika, Razia, Deepika, Grief, Katherine, Cherrier, Lauren, Omar, Ashraf, Walia, Rajat, Tokman, Sofya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Lung Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184979/ https://www.ncbi.nlm.nih.gov/pubmed/37197016 http://dx.doi.org/10.1097/TXD.0000000000001485

Ejemplares similares

Tacrolimus-Induced Hyponatremia in Lung Transplant Recipients: A Case Series
por: Banks, Paul N., et al.
Publicado: (2018)

Lung Transplant Candidates With Pretransplant Gastroesophageal Reflux and Antibodies to Lung Self-antigens Have Shorter CLAD-free Survival After Transplant
por: Razia, Deepika, et al.
Publicado: (2022)

(349) Molnupiravir vs Remdesivir for Treatment of Covid-19 in Lung Transplant Recipients
por: Razia, D., et al.
Publicado: (2023)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

EXCELLENT ALLOGRAFT RECOVERY DESPITE PROLONGED SARS-COV-2 SHEDDING AFTER REDUCTION OF IMMUNOSUPPRESSION IN LUNG TRANSPLANT RECIPIENT
por: RAZIA, DEEPIKA, et al.
Publicado: (2021)

PROLONGED COLONIZATION AND COISOLATION OF SARS-COV-2 IN UNVACCINATED RECIPIENTS OF LUNG TRANSPLANTS
por: RAZIA, DEEPIKA, et al.
Publicado: (2022)

Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: concern for immortal time bias effect
por: Riggs, Julie M., et al.
Publicado: (2023)

Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave
por: Al Jurdi, Ayman, et al.
Publicado: (2022)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Hospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease
por: Razia, Deepika, et al.
Publicado: (2023)

Decreased Lymphocytic Bronchitis Severity in the Era of Azithromycin Prophylaxis
por: Santos, Jesse, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

A Mixed-chimerism Protocol Utilizing Thymoglobulin and Belatacept Did Not Induce Lung Allograft Tolerance, Despite Previous Success in Renal Allotransplantation
por: Sommer, Wiebke, et al.
Publicado: (2021)

Response to letter entitled: Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: Concern for immortal time bias effect
por: Al Jurdi, Ayman, et al.
Publicado: (2023)

Impact of Postoperative Continuous Renal Replacement Therapy in Lung Transplant Recipients
por: Katahira, Masato, et al.
Publicado: (2020)

Detection of Bacterial Colonization in Lung Transplant Recipients Using an Electronic Nose
por: Wijbenga, Nynke, et al.
Publicado: (2023)

Assessment of Carfilzomib Treatment Response in Lung Transplant Recipients With Antibody-mediated Rejection
por: Pham, Christine, et al.
Publicado: (2021)

Postmortem Identification of Vascular Ehlers-Danlos Syndrome in a Lung Transplant Recipient
por: Chhabria, Mamta S., et al.
Publicado: (2023)

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients
por: Reese, Peter P., et al.
Publicado: (2023)

COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders
por: Kaminski, Hannah, et al.
Publicado: (2022)

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients
por: Hoffman, Thijs W., et al.
Publicado: (2020)

Lung cancer in recipients after lung transplant: single-centre experience and literature review
por: Lashari, Bilal Haider, et al.
Publicado: (2022)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

COVID-19 Has a High Mortality Rate in Lung Transplant Recipients: A Large Single-Center Experience
por: Razia, D., et al.
Publicado: (2022)

Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Fernández-Prada, María, et al.
Publicado: (2023)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

Outcomes of Critically Ill Lung Transplant Recipients with COVID-19
por: Razia, D., et al.
Publicado: (2022)

One Year Into the Pandemic: Evolving COVID-19 Outcomes in Lung Transplant Recipients, a Single-center Experience
por: Laothamatas, Kemarut, et al.
Publicado: (2022)

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan
por: Haraguchi, Mizuki, et al.
Publicado: (2023)

Assessment of dd-cfDNA Levels in Clinically Stable Lung Allograft Recipients Beyond the Initial 2 y Posttransplant
por: Trindade, Anil J., et al.
Publicado: (2022)

Treatment of a Pulmonary Aspergilloma in a Lung Transplant Recipient Using Catheter-directed Intracavitary Instillation of Liposomal Amphotericin B
por: Courtwright, Andrew M., et al.
Publicado: (2021)

(700) Vaccination with >2 Doses of Mrna Vaccines is Needed to Reduce Mortality Among Lung Transplant Recipients with Covid-19
por: Sindu, D., et al.
Publicado: (2023)

(698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
por: Sindu, D., et al.
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3tsohp12gijhk67uttcoe0ats4